Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

AMAG Pharmaceuticals Appoints Amit Verma as Vice President of Marketing



AMAG Pharmaceuticals Appoints Amit Verma as Vice President of Marketing

LEXINGTON, Mass., July 3, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc.
(Nasdaq:AMAG) today announced the appointment of Amit Verma as vice president
of marketing. Mr. Verma comes to AMAG with extensive marketing and sales
experience, most recently with the oncology division of Sanofi where he served
as the global commercial lead for JEVTANA, the only chemotherapeutic option
for advanced prostate cancer patients.

"Amit has a great deal of very relevant experience for AMAG's product
portfolio, in particular in oncology, where his insights will help shape our
marketing strategy for both Feraheme® and MuGard™," said Greg Madison, chief
commercial officer of AMAG. "With more than 15 years of commercial experience
in companies ranging from small biotechnology organizations to large
pharmaceutical companies, his contributions will be extremely valuable as we
strive to grow our products and add to our portfolio."

Prior to joining AMAG, Mr. Verma served as global commercial lead for JEVTANA
with Sanofi's oncology division, where he was responsible for launching the
product in over seventy countries worldwide. Before taking his role at Sanofi,
Mr. Verma was the senior director of marketing for Velcade at Millennium
Pharmaceuticals. He began his career in the pharmaceutical industry at
Novartis Pharmaceuticals Corporation. Mr. Verma received his MBA from Columbia
Business School and his BA from Hamilton College.

Inducement Equity Awards

In connection with Mr. Verma's joining the company, effective on the first day
of Mr. Verma's employment, Mr. Verma will be granted (i) an option to purchase
30,000 shares of common stock and (ii) 10,000 restricted stock units. The
option will have an exercise price equal to the closing price of AMAG's common
stock on the grant date and will be exercisable in four equal annual
installments beginning on the first anniversary of the grant date. The option
will have a ten-year term and be subject to the terms and conditions of the
stock option agreement pursuant to which the option will be granted. The
restricted stock units will vest in four equal annual installments beginning
on the first anniversary of the grant date and will be subject to the
restricted stock unit agreement pursuant to which the restricted stock units
will be granted. These equity awards will be granted without stockholder
approval as inducements material to Mr. Verma's entering into employment with
AMAG in accordance with NASDAQ Listing Rule 5635(c)(4).

About AMAG

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets
Feraheme® and MuGard™ in the United States. Along with driving organic growth
of its products, AMAG intends to expand its portfolio with additional
commercial-stage specialty products. The company is seeking complementary
products that leverage the company's commercial footprint and focus on
hematology and oncology centers and hospital infusion centers. For additional
company information, please visit www.amagpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements contained herein which do not describe
historical facts, including but not limited to statements regarding: Mr.
Verma's contributions to AMAG; the company's intent to drive organic growth of
our products; and the company's plans to seek complementary commercial
products to add to its portfolio are forward-looking statements which involve
risks and uncertainties that could cause actual results to differ materially
from those discussed in such forward-looking statements.

Such risks and uncertainties include: (1) uncertainties regarding our and
Takeda's ability to successfully compete in the intravenous iron replacement
market both in the US and outside the US, including the EU, (2) uncertainties
regarding our ability to compete in the oral mucositis market, (3)
uncertainties regarding our ability to successfully and timely complete our
clinical development programs and obtain regulatory approval for
Feraheme/Rienso in the broader IDA indication both in the US and outside of
the US, including the EU, (4) the possibility that significant safety or drug
interaction problems could arise with respect to Feraheme/Rienso or MuGard,
(5) uncertainties regarding the manufacture of Feraheme/Rienso or MuGard, (6)
uncertainties relating to our patents and proprietary rights, both in the US
and outside of the US, (7) the risk of an Abbreviated New Drug Application
(ANDA) filing following the FDA's recently published draft bioequivalence
recommendation for ferumoxytol, and (8) other risks identified in
our Securities and Exchange Commission filings, including our Quarterly Report
on Form 10-Q for the quarter ended March 31, 2013 and subsequent filings with
the SEC. We caution you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made.

We disclaim any obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or circumstances
on which any such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the forward-looking
statements.

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG
Pharmaceuticals, Inc.; MuGard is a trademark of Access Pharmaceuticals, Inc.

Rienso is a registered trademark of Takeda Pharmaceutical Company Limited.

CONTACT: AMAG Pharmaceuticals, Inc. Contact
         Amy Sullivan, 617-498-3303
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement